Data on prevalence of brain metastases at presentation in patients with nonesmall-cell lung cancer are limited. We queried the National Cancer Data Base to determine prevalence, risk factors and outcomes of patients with non esmall-cell lung cancer, presenting with brain metastases. Brain metastases were observed in 10.4% of patients, with median survival of 6 months. Risk of brain metastases at presentation may be calculated using 5 clinical variables. Background: Data on the prevalence of brain metastases at presentation in patients with nonesmall-cell lung cancer (NSCLC) are limited. We queried the National Cancer Data Base to determine prevalence, clinical risk factors, and outcomes of patients with NSCLC presenting with brain metastases. Patients and Methods: Patients with NSCLC diagnosed between 2010 and 2012 were identified using the National Cancer Data Base. The risk of brain metastases for individual variables was summarized by odds ratios and calculated using logistic regression analysis. The KaplanMeier product limit method was used to calculate the median and 1-, 2-, and 3-year overall survival (OS). Results: Brain metastases were observed in 47,546 (10.4%) of the 457,481 patients with NSCLC overall. The prevalence of brain metastases was much higher (26%) in patients with stage IV disease at presentation. On multivariate analysis, younger age, adenocarcinoma or large cell histology, tumor size > 3 cm, tumor grade II, and node-positive disease were associated with brain metastases. The prevalence of brain metastases ranged from as low as 0.57% in patients with only 1 risk factor to as high as 22% in patients with all 5 risk factors. The median and 1-, 2-, and 3-year OS for patients with brain metastases were 6 months and 29.9%, 14.3%, and 8.4%, respectively, with the 3-year OS increasing to 36.2% in those with T1/2 and N0/1 undergoing surgery for the primary site. Conclusions: In patients with NSCLC, the risk of brain metastases at presentation may be calculated based on 5 clinical variables. Selected patients with brain metastases at presentation may achieve prolonged benefit.
Introduction
Lung cancer is the leading cause of cancer-related death in the United States. 1 Nonesmall-cell lung cancer (NSCLC) accounts for 87% of lung cancer cases, and approximately 40% of patients are diagnosed with metastatic disease at presentation, with the most common sites of distant metastasis including the brain, liver, adrenal glands, and bones. [2] [3] [4] Brain metastases remain a significant problem in patients with lung cancer for several reasons. First, they are commonly observed, accounting for approximately one-half of all solid tumor metastases to the brain. 5, 6 Second, there has been an apparent stage migration resulting from the availability of modern staging imaging modalities, such as positron emission tomography and magnetic resonance imaging (MRI), which can detect subclinical brain lesions. And finally, with the modest improvement in survival resulting from systemic therapies that lack intracranial penetration, patients tend to live longer, with more time to develop brain metastases. 5, 7 The frequency of brain metastases at presentation in patients with NSCLC remains unknown. Several estimates have been reported in the literature, which have been limited by small sample 1 Division of Medical Oncology, Department of Medicine size and selection bias owing to the setting from which these patient samples are drawn. [8] [9] [10] Therefore, a large study examining the frequency of brain metastases and validation of previously described clinical risk factors, such as age, histology, and gender, may provide a better understanding of both the prevalence and risk factors for the development of brain metastases. 8, 11 We sought to systematically address these questions using the National Cancer Data Base, which captures data from approximately 70% of cancer cases in the United States and also includes data on brain metastases since 2010.
Patients and Methods
We searched the National Cancer Data Base registry data for patients with NSCLC diagnosed between 2010 and 2012 with complete data on brain metastases. Demographic and clinical variables included age at diagnosis, gender, race, histology, tumor size, tumor grade, lymph node status (N), and American Joint Committee on Cancer stage. Age at diagnosis was analyzed as a continuous variable. Tumor size was subdivided into 3 cm, 3.1 to 5 cm, 5.1 to 7 cm, and > 7 cm to match the American Joint Committee on Cancer Seventh Edition staging for T1, T2a, T2b, 
Statistical Analysis
Univariate and multivariate logistic regression analyses were used to explore the association of age at diagnosis, gender, race, tumor histology, tumor size, tumor grade, and N stage with the presence of brain metastases. All patients have data on age at diagnosis, gender, tumor histology (as a function of sample selection), and year of diagnosis. Missing data occurred in tumor grade (42%), tumor size (16.1%), and N stage (10.5%). Imputation of such a large amount of missing data was considered unreliable, and the missing values were included in a separate "unknown" category. Adjusted odds ratios (ORs) were calculated with 95% confidence intervals (CIs). The prevalence of brain metastases according to number of risk factors was also calculated, after dividing age into < 70 and 70 years. This cutoff was chosen as the median age at diagnosis for lung cancer is 70 years. 12 All statistical tests were 2-sided, and P < .05
was considered significant. Data analyses were performed using SAS 9.4 (SAS Institutes, Cary, NC). Overall survival (OS) was defined as time from diagnosis to death owing to any cause, and patients alive were censored at the last follow-up. Only those patients with vital status data available and with at least 1 month of follow-up were included for survival All statistical tests were 2-sided and P < .05 was considered significant are indicated in bold. Abbreviations: CL ¼ lower confidence interval limit; CU ¼ upper confidence interval limit; F ¼ female; M ¼ male.
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analysis. The Kaplan-Meier product limit method was used to calculate the median and 1-, 2-, and 3-year OS for patients with stage IV disease with or without brain metastases. Subsequent analyses for patients with brain metastases were performed to evaluate the outcomes according to the Charlson-Deyo comorbidity score and use of chemotherapy. The differences in Kaplan-Meier curves between these subgroups were compared using the log-rank test.
Patients with brain metastases, T1/T2, and N0/N1 were further evaluated according to the surgery of the primary site, with or without surgery of a distant site.
Results

Demographics
A total of 511,050 patients were identified who met the inclusion criteria, of whom we excluded 53,569 patients owing to missing data regarding brain metastases, leaving 457,481 patients in the final cohort (Figure 1 ). Most patients were men (52%) and of white race (85.2%). The median age was 69 years (range, 18-90 years). The histologic distribution included 235,341 patients (51.4%) with adenocarcinoma, 134,046 (29.3%) with squamous cell carcinoma, 5455 (1.2%) with large-cell carcinoma, and 82,639 (18.1%) with other histologies (Table 1) 
Risk Factors for Brain Metastases
Brain metastases were detected in 47,546 (10.4%) of the 457,481 patients in the total cohort, and the frequency of brain metastases was similar in men (10.4%) and women (10.3%). The prevalence of brain metastases was higher (26%) in patients with All statistical tests were 2-sided and P < .05 was considered significant are indicated in bold. Abbreviation: CI ¼ confidence interval. Age was re-categorized into < 70 or 70 years, and the prevalence of brain metastases was calculated according to number of risk factors, including age < 70 years, tumor size > 3 cm, adenocarcinoma or large cell histology, tumor grade 2, and node-positive disease (N1-N3). The prevalence of brain metastases ranged from as low as 0.57% in patients with only 1 risk factor to as high as 22% in patients with all 5 risk factors (Table 3) .
Survival Analysis for Patients With Stage IV Disease
The median follow-up time for survivors was 27.5 months (range, 1.0-61.3 months). The median OS for all patients with stage IV disease during this time period was 7.1 months (95% CI, 7.0-7.1 months), with 1-, 2-, and 3-year survivals of 33.7%, 16.6%, and 9.7%, respectively. The median OS for patients with brain metastases was significantly worse than in patients without brain metastases (6 vs. 7.5 months; log rank c 2 , 324; P < .001). The 1-, 2-, and 3-year survival rates were 35.1%, 17.4%, and 10.2%, respectively, for patients without brain metastases, and 29.9%, 14.3%, and 8.4%, respectively, for patients with brain metastases (Figure 2) .
The median OS for patients with brain metastases and Charlson-Deyo comorbidity score of 0, 1, and 2 were 7.1 months, 5.4 months, and 4.4 months, respectively (log-rank c 2 , 321.6; 2 df; P < .001). The median OS for patients with brain metastases was significantly higher in those who received chemotherapy, compared with those who did not receive chemotherapy (9.4 vs.
3.3 months; log-rank c 2 , 2279.1; 1 df; P < .0001).
A subset of 561 patients with brain metastases who had T1/T2 and N0/N1 stage and underwent surgery of the primary site had a median OS of 21.4 months, with OS rates at 1, 2, and 3 years being 69.2%, 45.5%, and 36.2%, respectively (Figure 3 ). Within this patient subset, 237 (42%) patients also had surgical resection of a distant site. In this patient population, the median and 1-, 2-, and 3-year OS were 26.5 months, 79.1%, 53.2%, and 48.6%, respectively. 
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Discussion
In our study, brain metastases were found in 10.4% of patients with newly diagnosed NSCLC and 26% of patients with stage IV disease. This underscores the importance of routine brain MRI for staging in patients with newly diagnosed NSCLC. This rate of brain metastases is numerically higher than the 8.3% that we had previously described in patients diagnosed between 1988 and 1997, likely owing to the widespread availability of brain MRI during the time period of the present study. 13 Our study substantiates findings from previous studies that link nonsquamous histology, younger age, tumor size, and nodal station involvement to the development of brain metastases. [13] [14] [15] [16] Patients with brain metastases and T1/T2 and N0/N1 disease who underwent surgery are a unique patient subset with better prognosis. The increased percentage of long-term survivors in this patient population may reflect the current practice of aggressive surgical and modern stereotactic radiotherapy interventions for the treatment of brain metastases in this selected subgroup. [17] [18] [19] [20] [21] Our study has several limitations, including its retrospective nature, lack of information regarding how patients were staged, knowledge of molecular subtype, and specific chemotherapy drugs or targeted therapies given. Nevertheless, this is the largest study of patients with brain metastases at presentation to date, allowing for a more detailed evaluation of its risk factors.
NSCLC is a disease characterized by both intertumor and intratumor molecular heterogeneity. The molecular analysis of patientmatched paired primary lung and brain metastases has implicated several, including PI3K/AKT/mTOR, HER2/EGFR, and MAPK CDK pathways in driving brain metastases, which may be therapeutically targeted. 22, 23 Several agents, including small molecule EGFRtyrosine kinase inhibitors and next generation ALK inhibitors, are already approved by the United States Food and Drug Administration for patients with EGFR-mutant and ALKerearrangement-positive NSCLC, with promising intracranial activity. With the advent of immunotherapy and approval of pembrolizumab and nivolumab for the treatment of metastatic NSCLC, the intracranial activity of these agents is also being investigated. [24] [25] [26] Our study provides the most comprehensive clinical predictor data for the brain metastases at presentation and may serve as a baseline for the contribution of individual clinical variables as predictors for brain metastases to be used in combination with the new molecular predictors.
Conclusions
Brain metastases are seen in 10.4% of patients with NSCLC at presentation. The incidence of brain metastases at presentation may be estimated based on age, histology, tumor size, tumor grade, and lymph node involvement. Selected patients with brain metastases at presentation may achieve prolonged benefit. 
Clinical Practice Points
Lung cancer is the leading cause of cancer-related death. Brain metastases remain a significant problem in patients with NSCLC owing to their common occurrence during the course of the disease. The frequency of brain metastases at presentation in patients with NSCLC and the clinical risk factors remain unknown. We sought to systematically address these questions using the NCDB, which captures data from approximately 70% of cancer cases in the United States and also includes data on brain metastases since 2010. Brain metastases were observed in 47,546 (10.4%) of the 457,481 patients with NSCLC overall. The prevalence of brain metastases was higher (26%) in patients with stage IV disease at presentation. On multivariate analysis, younger age, adenocarcinoma or large cell histology, tumor size > 3 cm, tumor grade> II, and nodepositive disease were associated with brain metastases. The prevalence of brain metastases ranged from as low as 0.57% in patients with only 1 risk factor to as high as 22% in patients with all 5 risk factors. The median and 1-, 2-, and 3-year OS for patients with brain metastases were 6 months and 29.9%, 14.3%, and 8.4%, respectively, with the 3-year OS increasing to 36.2% in those with T1/2 and N0/1 undergoing surgery for the primary site. In patients with NSCLC, the risk of brain metastases at presentation may be calculated based on 5 clinical variables. Selected patients with brain metastases at presentation may achieve prolonged benefit.
